Poolbeg Pharma PLC (LON:POLB – Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as GBX 7 ($0.09) and last traded at GBX 7.40 ($0.09), with a volume of 2840506 shares changing hands. The stock had previously closed at GBX 7.65 ($0.10).
Poolbeg Pharma Stock Down 3.3 %
The firm has a 50 day moving average price of GBX 8.49 and a 200 day moving average price of GBX 11.25. The stock has a market cap of £37.00 million, a P/E ratio of -760.00 and a beta of 2.11.
Poolbeg Pharma Company Profile
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Featured Articles
- Five stocks we like better than Poolbeg Pharma
- Stock Splits, Do They Really Impact Investors?
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- The Significance of Brokerage Rankings in Stock Selection
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- What is Short Interest? How to Use It
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
